Published in Am J Nephrol on August 30, 2012
Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant (2012) 1.10
Magnesium in disease prevention and overall health. Adv Nutr (2013) 1.04
Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int (2013) 0.96
Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One (2014) 0.88
Serum Magnesium and Sudden Death in European Hemodialysis Patients. PLoS One (2015) 0.87
Magnesium and cardiovascular complications of chronic kidney disease. Nat Rev Nephrol (2015) 0.87
Hypomagnesemia Is Associated with Increased Mortality among Peritoneal Dialysis Patients. PLoS One (2016) 0.83
Low Magnesium Levels and FGF-23 Dysregulation Predict Mitral Valve Calcification as well as Intima Media Thickness in Predialysis Diabetic Patients. Int J Endocrinol (2015) 0.80
Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease. Kidney Int (2015) 0.79
Clinical features of CKD-MBD in Japan: cohort studies and registry. Clin Exp Nephrol (2016) 0.78
Effects of Magnesium on the Phosphate Toxicity in Chronic Kidney Disease: Time for Intervention Studies. Nutrients (2017) 0.78
Magnesium in CKD: more than a calcification inhibitor? J Nephrol (2014) 0.77
Association between Density of Coronary Artery Calcification and Serum Magnesium Levels among Patients with Chronic Kidney Disease. PLoS One (2016) 0.76
Serum Magnesium Levels and Hospitalization and Mortality in Incident Peritoneal Dialysis Patients: A Cohort Study. Am J Kidney Dis (2016) 0.75
Low Magnesium Exacerbates Osteoporosis in Chronic Kidney Disease Patients with Diabetes. Int J Endocrinol (2015) 0.75
Lack of influence of serum magnesium levels on overall mortality and cardiovascular outcomes in patients with advanced chronic kidney disease. ISRN Nephrol (2013) 0.75
Dietary Habits and Risk of Kidney Function Decline in an Urban Population. J Ren Nutr (2016) 0.75
Reduced Mortality in Maintenance Haemodialysis Patients on High versus Low Dialysate Magnesium: A Pilot Study. Nutrients (2017) 0.75
Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol (2007) 3.06
Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant (2008) 2.42
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24
Electrocardiographic P-wave characteristics in patients with end-stage renal disease: P-index and interatrial block. Int Urol Nephrol (2012) 2.12
The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis (2006) 2.01
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant (2007) 1.91
Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90
Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrol Dial Transplant (2013) 1.88
FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int (2010) 1.81
Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol (2011) 1.77
Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int (2004) 1.72
The accuracy of home glucose meters in hypoglycemia. Diabetes Technol Ther (2010) 1.68
Unusual features in a patient with neurofibromatosis type 1: multiple subcutaneous lipomas, a juvenile polyp in ascending colon, congenital intrahepatic portosystemic venous shunt, and horseshoe kidney. Am J Med Genet A (2004) 1.67
Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant (2010) 1.65
Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.65
Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters. Nephrol Dial Transplant (2013) 1.62
Clinical findings in the renal victims of a catastrophic disaster: the Marmara earthquake. Nephrol Dial Transplant (2002) 1.60
Prostate cancer and adiponectin. Urology (2005) 1.59
Traumatic intrusion of primary teeth and its effects on the permanent successors: a clinical follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 1.58
Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab (2014) 1.57
Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis (2011) 1.55
Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant (2006) 1.53
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif (2007) 1.51
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol (2013) 1.50
Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant (2011) 1.50
Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig Dis Sci (2007) 1.45
Negative outcome studies in end-stage renal disease: how dark are the storm clouds? Nephrol Dial Transplant (2007) 1.44
A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol (2011) 1.40
The protein science of biosimilars. Nephrol Dial Transplant (2006) 1.36
Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int (2013) 1.35
Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant (2010) 1.34
Timing of replacement therapy for acute renal failure after cardiac surgery. J Card Surg (2004) 1.33
Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2005) 1.30
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant (2013) 1.28
Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol (2008) 1.27
Improvement in nutritional parameters after initiation of chronic hemodialysis. Am J Kidney Dis (2002) 1.26
Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int (2004) 1.25
Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.22
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract (2006) 1.21
Pulmonary hypertension in CKD. Am J Kidney Dis (2012) 1.19
Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif (2009) 1.19
Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis. Nephrol Dial Transplant (2006) 1.16
Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.13
Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens (2006) 1.12
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant (2010) 1.11
Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. Nephrol Dial Transplant (2008) 1.11
Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.10